Highlights
The 4D trial provides robust evidence for the use of dexmedetomidine in managing hyperactive delirium among non-intubated patients. Key takeaways include:
- Dexmedetomidine significantly improved a joint primary endpoint encompassing agitation duration, delirium duration, and the risk of intubation.
- The median duration of agitation was reduced by approximately 50%, falling from 2 hours in the placebo group to 1 hour in the dexmedetomidine group.
- The study was terminated early due to clear evidence of efficacy at the preplanned interim analysis.
- Safety profiles regarding bradycardia and hypotension were comparable between the dexmedetomidine and placebo groups in this specific cohort.
